Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease

A technology of Viper akistrosus and thrombin, which is applied in the field of Viper akistrosus thrombin and Viper akistrosus thrombin for the preparation of drugs for the treatment of hemorrhagic diseases, and can solve the problem of no snake distribution

Inactive Publication Date: 2004-04-14
GUANGZHOU RUIKANG BIOLOGICAL PHARMA
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The raw material of Reptilase is the venom of Bothrop

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1. Effect of Agkistrodon akistrodon thrombin on mouse tail-cutting bleeding time:

[0048] 50 healthy Kunming mice, half male and half male, were randomly divided into 5 groups according to body weight, i.e. high-dose group (0.48U / kg), middle-dose group (0.24U / kg), low-dose group ( 0.12U / kg), the positive control hemostatic group (0.24U / kg) and the negative control sterile water for injection group. One-time tail vein injection was used. 30 minutes after the administration, the tail was quickly cut off about 1 cm above the tip of the mouse tail with very sharp scissors, and the time was immediately recorded with a stopwatch, and the blood flowing out was continuously sucked with filter paper. The period from the beginning of tail-cutting to the cessation of bleeding is the tail-cutting bleeding time of mice. SPSS8.0 statistical software was used for statistical analysis, and the test method was t test. The results are shown in Table 1. The results in Table 1 ...

Embodiment 2

[0058] Example 2. The effect of Agkistrodon akistrodon thrombin on the bleeding time of rabbit ear vein:

[0059] 30 healthy Japanese big-eared white rabbits were randomly divided into 5 groups according to body weight, 6 in each group, half male and half male, and the 5 groups were: Agkistrodon akistrosus high-dose thrombin group (0.16U / kg), middle-dose group (0.08 U / kg), low dose group (0.04U / kg), positive control Lizhizhi group (0.04U / kg) and negative control sterile water for injection group. The 3 Agkistrodon akistrosus thrombin groups and Lizhixue group were injected into rabbit ear margin once according to the designed dose of the experiment, and the negative control group was given an equal volume of sterilized water for injection. After 30 minutes of administration, puncture the ear vein area of ​​the ear tip of rabbits that have been sheared and disinfected with a disposable blood collection needle, start counting the time after bleeding from the wound surface, and g...

Embodiment 3

[0069] Example 3. The influence of Agkistrodon akistrodon thrombin on the clotting time of rabbit whole blood:

[0070]24 healthy Japanese big-eared white rabbits were randomly divided into 4 groups according to body weight, with 6 rabbits in each group, namely high-dose group (0.16U / kg), middle-dose group (0.08U / kg), low-dose group (0.08U / kg) group (0.04U / kg) and Lizhizhi group (0.04U / kg). First, the normal coagulation time of each rabbit was determined as its own blank control, and then, according to the experimental design, the dose was administered through the ear vein of the rabbit once, 5min, 30min, 1h, 3h, 6h, 12h and 24h after administration, respectively. The middle artery of the rabbit ear was punctured with a disposable blood collection needle, and 1ml of blood was collected and put into a sterilized glass test tube. The glass test tube was placed in a 37°C water bath, and the time was recorded. Then tilt the test tube to see if the blood coagulates until the blood...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention refers to a ThrombinLikeEnzyme, called Haemocoagulase Acutus, in brief Halase, separated and purified from Agkistrodon acutus midew. It also refers to the usage of the drug of curing haemorrhagic disease made by using Halase. Halase is a glycoprotein composed of double sub-groups, connected by bisulfur bond. On N end, determining result of 15 amino acid sequences as follows: A sub-group: DCPSDWSSYEGHCYK; Bsub-group: DCSSGWSS- YEGHCYK. Molecular weight: 29076.1Da, equipotential point 5.78, and containing 1.89%-1.95% neutral hexose. Take Halase and excipient dextrose to add in injection water to dissolve, filter and sterilize, make split charging, and freeze-dry to obtain white injecting Halase powder injection. Halase is a new haemostatic drug.

Description

technical field [0001] The invention relates to a thrombin-like enzyme isolated and purified from Agkistrodon acutus venom, which is named as Haemocoagulase Acutus (Halase for short). The invention also relates to the application of the Agkistrodon akistrodon thrombin for preparing medicine for treating hemorrhagic diseases. Background technique [0002] In clinical emergency medicine, bleeding is a frequent emergency. Bleeding can be divided into two categories according to the cause of bleeding: one is blood disease or bleeding disease, which is often spontaneous bleeding caused by the disorder of the body's coagulation function. Bleeding disorders can be primary or secondary to various clinical diseases, such as thrombocytopenic purpura, hemophilia, aplastic anemia, leukemia, hypertensive encephalopathy, digestive system diseases, gastrointestinal bleeding, etc. The other type is bleeding caused by vascular tissue damage caused by injury or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00A61P7/04C12N9/74
CPCC12N9/6429C12Y304/21005A61K38/00A61P7/04
Inventor 吴忠
Owner GUANGZHOU RUIKANG BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap